The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol--the so-called "bad" cholesterol--by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study has found. Results from the study sponsored by Regeneron, are being presented as "late breaking science" at the American Heart Association Scientific Sessions 2020 on Sunday, November 15, and simultaneously published in The New England Journal of Medicine.
Evinacumab is a fully human monoclonal antibody that works through a different mechanism than existing drugs to bring dangerously high cholesterol to normal levels when combined with maximally-tolerated lipid-lowering therapies in people with familial hypercholesterolemia, a common inherited condition that is difficult to treat.
"Our study assessing the safety and efficacy of evinacumab shows that it can lower LDL cholesterol by half in patients unable to attain target guidelines despite maximally tolerated lipid lowering therapy," says principal investigator. "Evinacumab is a fully human monoclonal antibody that inhibits angiopoietin like protein 3 (ANGPLT3) and lowers LDL cholesterol through an LDL receptor independent pathway. Genetic studies have shown that people who are missing or have low levels of ANGPTL3 are known to have very low lifelong levels of LDL cholesterol and rarely suffer from atherosclerotic cardiovascular disease."
In the United States, approximately 7 percent of adults have been diagnosed with severe hypercholesterolemia, which is defined as having untreated LDL cholesterol at levels greater than or equal to 190 mg per deciliter. Familial hypercholesterolemia is present in 1 in 313 people, but it is far more common in patients with early-onset cardiovascular disease, occurring in 1 in 15. The 2018 American Heart Association/American Congress of Cardiology recommends an LDL cholesterol goal of less than or equal to 70 mg per deciliter in patients with very high risk of atherosclerotic cardiovascular disease, and more aggressive targets have been established by the European Society of Cardiology guideline with recommendations to lower LDL cholesterol to 55 mg/dL or below. These goals have proven difficult for patients with hypercholesterolemia to reach through standard "triple therapy" of a high-intensity statin, a PCSK9 inhibitor, and ezetimibe, a drug that limits the absorption of cholesterol from the intestine.
"There's an unmet need for agents that address refractory hypercholesterolemia through a pathway that's independent of the LDL receptor," explains the author. "If approved by the U.S. Food and Drug Administration, evinacumab may potentially fills that clinical gap for patients, by reducing severely elevated LDL cholesterol."
The phase 2 multi-center, double-blinded, placebo-controlled study of evinacumab included 272 patients with primary hypercholesterolemia including a majority having a diagnosis of heterozygous familial hypercholesterolemia (HeFH). HeFH is an inherited form of hypercholesterolemia most often caused by mutations in the LDL receptor gene. The research team found that subcutaneous administration of the agent at 450 mg weekly resulted in LDL cholesterol lowering of 56 percent, and 52.9 percent at 300 mg weekly compared to the placebo group. With monthly intravenous administration of evinacumab at 15 mg/kg, LDL cholesterol reduction was 50.5 percent compared to the placebo group. All patients receiving evinacumab were on background lipid-lowering therapies.
Evinacumab was well-tolerated among most patients. One patient treated with subcutaneous evinacumab had difficulty breathing, and another had a mild anaphylactic reaction. Both stopped the medication and their symptoms improved with other treatment. Two deaths were reported in the trial but were linked to underlying health conditions.
"Our study demonstrates that a regimen of either subcutaneous or intravenous evinacumab can have a significant impact on LDL cholesterol," notes the author. "If approved for use in this setting, evinacumab could potentially arm cardiologists with a major new add-on therapy to bring patients with HeFH to or closer to their cholesterol-lowering goal."
Evinacumab is under regulatory review in the United States and the European Union as an adjunct to other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia, another form of familial hypercholesterolemia.
https://www.mountsinai.org/about/newsroom/2020/a-novel-monoclonal-antibody-therapy-cuts-ldl-cholesterol-by-half-in-a-high-risk-patient-population-pr
https://www.nejm.org/doi/full/10.1056/NEJMoa2031049
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fevinacumab-in-patients&filter=22
A novel monoclonal antibody therapy in a phase 2 trail cuts LDL cholesterol by half
- 959 views
- Added
Edited
Latest News
More influence of environme…
By newseditor
Posted 24 Apr
The assembly of the human c…
By newseditor
Posted 24 Apr
Wiring of the human neocortex
By newseditor
Posted 24 Apr
Abusive drugs hijack natura…
By newseditor
Posted 23 Apr
Mechanism of action of the…
By newseditor
Posted 23 Apr
Other Top Stories
Selective inhibition of peanut-specific antibodies
Read more
A gene implicated in protection against neuroinflammation
Read more
Immune alterations associated with progression of lung cancer
Read more
Structure and degradation of circular RNAs regulate PKR activation…
Read more
How scratching may prime children with eczema for food allergy and…
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Massively parallel screen u…
By newseditor
Posted 24 Apr
Distinct genetic and enviro…
By newseditor
Posted 24 Apr
Hippocampus-to-amygdala pat…
By newseditor
Posted 24 Apr
Integrative spatial analysi…
By newseditor
Posted 24 Apr
Time-series reconstruction…
By newseditor
Posted 24 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar